ADDAB koom tes nrog Mayo Clinic1
Ib qho kev sib koom ua tswv cuab tom ntej ADC platform
Raws li kev ua haujlwm ntawm Svetomir Markovic thiab cov npoj yaig ntawm Mayo Clinic2,3
Ua kom muaj kev sib txuas ntawm cov tshuaj tiv thaiv rau cov tshuaj them nyiaj rau oncology thiab dhau mus
Circumvents qhov xav tau rau:
- Siv covalent "linker" technology
- Internalization nyob rau hauv lub cell
Paub, kho cov tshuaj tiv thaiv kab mob yog tsis-covalently khi rau cov tshuaj payloads los ntawm kev tsim kho ntawm patented admixture ntawm
- Ib los yog ntau tshaj kho los yog immunologically active antibodies
- Ib qho "particle" ntawm albumin
- Cov tshuaj payload
Tus kws tshawb nrhiav tau pib ua pov thawj ntawm cov kev tshawb fawb lub tswv yim tseem nyob hauv B cell lymphoma, melanoma, thiab qog noj ntshav gynecological.
Cov cuab yeej cuab tam muaj peev xwm suav nrog 17 tsev neeg patent, 32 patents tso cai rau hnub tim nrog lub neej dhau los ntawm tsawg kawg yog 2035 thiab lwm 135 patents tseem tos.
1) Xyoo 2020, Sorrento tau txais daim ntawv tso cai tshwj xeeb los tsim thiab ua lag luam ANNAB koom tes nrog Mayo Clinic
2) Nevala W, et al. Antibody-targeted chemotherapy rau kev kho mob ntawm melanoma. Cancer Res. 2016; 76: 3954-3964. 2
3) Butterfield JT, et al. Kev txheeb xyuas ntawm peptide-peptide binding motif hauv txheej ntawm nab-paclitaxel nanoparticles nrog cov tshuaj tiv thaiv kab mob: bevacizumab, rituximab, thiab trastuzumab. Sci Rep. 2017; 7:14476 ua.